1. Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection.
- Author
-
Tamir H, Melamed S, Erez N, Politi B, Yahalom-Ronen Y, Achdout H, Lazar S, Gutman H, Avraham R, Weiss S, Paran N, and Israely T
- Subjects
- Angiotensin-Converting Enzyme 2 genetics, Angiotensin-Converting Enzyme 2 immunology, Animals, Cytokine Release Syndrome immunology, Cytokine Release Syndrome prevention & control, Disease Models, Animal, Female, Humans, Lung immunology, Lung virology, Mice, Mice, Transgenic, SARS-CoV-2 immunology, Toll-Like Receptor 3 immunology, Viral Load drug effects, COVID-19 Drug Treatment, COVID-19 immunology, COVID-19 prevention & control, Immunity, Innate, Poly I-C immunology, Poly I-C therapeutic use, SARS-CoV-2 drug effects, Toll-Like Receptor 3 agonists
- Abstract
SARS-CoV-2, a member of the coronavirus family, is the causative agent of the COVID-19 pandemic. Currently, there is still an urgent need in developing an efficient therapeutic intervention. In this study, we aimed at evaluating the therapeutic effect of a single intranasal treatment of the TLR3/MDA5 synthetic agonist Poly(I:C) against a lethal dose of SARS-CoV-2 in K18-hACE2 transgenic mice. We demonstrate here that early Poly(I:C) treatment acts synergistically with SARS-CoV-2 to induce an intense, immediate and transient upregulation of innate immunity-related genes in lungs. This effect is accompanied by viral load reduction, lung and brain cytokine storms prevention and increased levels of macrophages and NK cells, resulting in 83% mice survival, concomitantly with long-term immunization. Thus, priming the lung innate immunity by Poly(I:C) or alike may provide an immediate, efficient and safe protective measure against SARS-CoV-2 infection.
- Published
- 2022
- Full Text
- View/download PDF